We are live on ! Find out more
LOXO

Loxo Oncology, Inc
LOXO

Delisted

LOXO was delisted on the 14th of February, 2019.

129 hedge funds and large institutions have $2.4B invested in Loxo Oncology, Inc in 2017 Q2 according to their latest regulatory filings, with 47 funds opening new positions, 49 increasing their positions, 24 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,075% more first-time investments, than exits

New positions opened: 47 | Existing positions closed: 4

267% more funds holding in top 10

Funds holding in top 10: 311 (+8)

113% more capital invested

Capital invested by funds: $1.12B → $2.4B (+$1.27B)

104% more repeat investments, than reductions

Existing positions increased: 49 | Existing positions reduced: 24

50% more funds holding

Funds holding: 86129 (+43)

63% less call options, than puts

Call options by funds: $2.09M | Put options by funds: $5.7M

Holders
129
Holders Change
+43
Holders Change %
+50%
% of All Funds
3.22%
Holding in Top 10
11
Holding in Top 10 Change
+8
Holding in Top 10 Change %
+266.67%
% of All Funds
0.27%
New
47
Increased
49
Reduced
24
Closed
4
Calls
$2.09M
Puts
$5.7M
Net Calls
-$3.62M
Net Calls Change
-$3.62M
Name Holding Trade Value Shares
Change
Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$352M +$26.2M +472,814 +12%
AC
2
Aisling Capital
New York
$336M
Wellington Management Group
3
Wellington Management Group
Massachusetts
$196M +$659K +11,893 +0.5%
O
4
OrbiMed
New York
$139M
BlackRock
5
BlackRock
New York
$129M +$15.1M +273,291 +21%
Adage Capital Partners
6
Adage Capital Partners
Massachusetts
$103M -$9.9M -178,694 -12%
AllianceBernstein
7
AllianceBernstein
Tennessee
$75.1M +$17.3M +312,988 +50%
Vanguard Group
8
Vanguard Group
Pennsylvania
$73.4M +$10.1M +181,471 +25%
Victory Capital Management
9
Victory Capital Management
Texas
$64.2M -$29.5M -531,570 -40%
Lord, Abbett & Co
10
Lord, Abbett & Co
New Jersey
$59.3M +$32.3M +582,862 +372%
PC
11
Paulson & Co
New York
$55.1M -$6.96M -125,607 -15%
O
12
OppenheimerFunds
New York
$52.9M +$36.5M +659,486 New
State Street
13
State Street
Massachusetts
$43.3M -$413K -7,462 -1%
EAM
14
Eventide Asset Management
Massachusetts
$42.5M -$2.72M -49,000 -8%
BI
15
BVF Inc
California
$37.2M +$7.94M +143,386 +45%
MWNA
16
Marshall Wace North America
New York
$33.3M +$23.1M +416,838 New
Franklin Resources
17
Franklin Resources
California
$30.6M -$13.9M -250,389 -40%
T. Rowe Price Associates
18
T. Rowe Price Associates
Maryland
$30.5M +$20.7M +374,089 +5,894%
PC
19
Polar Capital
United Kingdom
$29.7M +$3.87M +69,785 +23%
CC
20
Casdin Capital
New York
$28.9M
DCM
21
Driehaus Capital Management
Illinois
$28.7M -$13.4M -241,222 -40%
DCM
22
DAFNA Capital Management
California
$24.3M +$161K +2,899 +1%
RSCM
23
Rock Springs Capital Management
Maryland
$23.1M +$5.93M +107,000 +59%
Northern Trust
24
Northern Trust
Illinois
$20.7M +$2.51M +45,272 +21%
DM
25
Deerfield Management
New York
$20.1M -$27.8M -502,133 -67%

LOXO Hedge Fund Activity: Q2 2017 in Review

129 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Loxo Oncology, Inc (LOXO) for Q2 2017, worth a combined $2.4B — up 113% from $1.12B a quarter earlier.

Buyers outnumbered sellers: 47 funds opened new LOXO positions and 4 closed out — a net gain of 43 holders — while 49 added to existing stakes and 24 trimmed.

The largest buyer was OppenheimerFunds, opening a new position worth an estimated $36.5M. The largest seller was Victory Capital Management, cutting an estimated $29.5M.

  • 129 institutional investors held Loxo Oncology, Inc (LOXO) as of Q2 2017, up from 86 in Q1 2017.
  • Funds reported $2.4B of Loxo Oncology, Inc stock for Q2 2017, up 113% quarter-over-quarter.
  • 47 funds opened new Loxo Oncology, Inc positions in Q2 2017 and 4 closed out, a net change of +43 holders.
  • The largest Loxo Oncology, Inc buyer in Q2 2017 was OppenheimerFunds, an estimated $36.5M added.
  • The largest Loxo Oncology, Inc seller in Q2 2017 was Victory Capital Management, an estimated $29.5M sold.

Based on aggregated 13F filings for Q2 2017.